MeiLan K. Han

40.2k total citations · 7 hit papers
324 papers, 13.8k citations indexed

About

MeiLan K. Han is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Health, Toxicology and Mutagenesis. According to data from OpenAlex, MeiLan K. Han has authored 324 papers receiving a total of 13.8k indexed citations (citations by other indexed papers that have themselves been cited), including 295 papers in Pulmonary and Respiratory Medicine, 106 papers in Physiology and 19 papers in Health, Toxicology and Mutagenesis. Recurrent topics in MeiLan K. Han's work include Chronic Obstructive Pulmonary Disease (COPD) Research (261 papers), Respiratory Support and Mechanisms (101 papers) and Asthma and respiratory diseases (92 papers). MeiLan K. Han is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (261 papers), Respiratory Support and Mechanisms (101 papers) and Asthma and respiratory diseases (92 papers). MeiLan K. Han collaborates with scholars based in United States, United Kingdom and Canada. MeiLan K. Han's co-authors include Fernando J. Martínez, Jeffrey L. Curtis, Gerard J. Criner, Barry J. Make, George R. Washko, Edwin K. Silverman, Mark T. Dransfield, David A. Lynch, Ella A. Kazerooni and James D. Crapo and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

MeiLan K. Han

293 papers receiving 13.6k citations

Hit Papers

Once-Daily Single-Inhaler Triple versus Dua... 2010 2026 2015 2020 2018 2011 2010 2012 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
    2018 758 citations Gerard J. Criner, Mark T. Dransfield et al. profile →
  2. Analysis of the Lung Microbiome in the “Healthy” Smoker and in COPD
    2011 726 citations MeiLan K. Han, Jeffrey L. Curtis et al. profile →
  3. Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
    2010 726 citations MeiLan K. Han, Àlvar Agustí et al. American Journal of Respiratory and Critical Care Medicine profile →
  4. Computed tomography–based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression
    2012 493 citations MeiLan K. Han, Ella A. Kazerooni et al. profile →
  5. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function
    2016 418 citations Prescott G. Woodruff, R. Graham Barr et al. profile →
  6. Pulmonary Arterial Enlargement and Acute Exacerbations of COPD
    2012 320 citations George R. Washko, MeiLan K. Han et al. profile →
  7. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision
    2022 244 citations Bartolomé R. Celli, Gerard J. Criner et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers

MeiLan K. Han
Gerard J. Criner United States
Frank C. Sciurba United States
Harvey O. Coxson Canada
Barry J. Make United States
George R. Washko United States
Ruth Tal‐Singer United States
Mark T. Dransfield United States
Roberto Rodríguez-Roisin Spain
Nicola A. Hanania United States
David A. Lomas United Kingdom
Gerard J. Criner United States
MeiLan K. Han
Citations per year, relative to MeiLan K. Han MeiLan K. Han (= 1×) peers Gerard J. Criner

Countries citing papers authored by MeiLan K. Han

Since Specialization
Citations

This map shows the geographic impact of MeiLan K. Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MeiLan K. Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MeiLan K. Han more than expected).

Fields of papers citing papers by MeiLan K. Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MeiLan K. Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MeiLan K. Han. The network helps show where MeiLan K. Han may publish in the future.

Co-authorship network of co-authors of MeiLan K. Han

This figure shows the co-authorship network connecting the top 25 collaborators of MeiLan K. Han. A scholar is included among the top collaborators of MeiLan K. Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MeiLan K. Han. MeiLan K. Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martinez, Fernando J., John R. Hurst, MeiLan K. Han, et al.. (2025). Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial. ERJ Open Research. 11(6). 324–2025.
2.
Lingappan, Krithika, Isaac K. Sundar, Y. S. Prakash, et al.. (2025). Addressing Sex as a Biological Variable in Preclinical Models of Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine. 211(8). 1346–1368.
3.
Ross, James C., Raúl San Jośe Estépar, Samuel Y. Ash, et al.. (2024). Dysanapsis is differentially related to lung function trajectories with distinct structural and functional patterns in COPD and variable risk for adverse outcomes. EClinicalMedicine. 68. 102408–102408. 9 indexed citations
4.
Han, MeiLan K., et al.. (2024). Striving for Stability in Patients with COPD: A New Way Forward?. Advances in Therapy. 41(11). 3977–3981. 4 indexed citations
5.
Pugashetti, Janelle Vu, J. Kim, Swaraj Bose, et al.. (2024). Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis. A1006–A1006.
6.
Lodge, Caroline, E. Haydn Walters, Dinh Bui, et al.. (2024). Can We Use Lung Function Thresholds and Respiratory Symptoms to Identify Pre-Chronic Obstructive Pulmonary Disease? A Prospective, Population-based Cohort Study. American Journal of Respiratory and Critical Care Medicine. 209(12). 1431–1440. 12 indexed citations
7.
8.
Ho, Lawrence, Nishant Gupta, Joel Moss, et al.. (2024). Unsupervised Exercise in Interstitial Lung Disease. CHEST Journal. 166(5). 1108–1123. 2 indexed citations
9.
Singh, Dave, MeiLan K. Han, Nathaniel M. Hawkins, et al.. (2024). Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Advances in Therapy. 41(6). 2151–2167. 34 indexed citations
10.
Krishnan, Jamuna K., Musarrat Nahid, Aaron Baugh, et al.. (2023). Disparities in Guideline-Concordant Statin Treatment in Individuals With Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 10(4). 369–379. 2 indexed citations
11.
Sin, Don D., Dany Doiron, Àlvar Agustí, et al.. (2023). Air pollution and COPD: GOLD 2023 committee report. European Respiratory Journal. 61(5). 2202469–2202469. 75 indexed citations
12.
Lee, J.S., Andrea Oh, Jonathan Goldin, et al.. (2023). COMPUTER-ASSISTED QUANTITATIVE IMAGE ANALYSIS FOR IDENTIFICATION OF PULMONARY FIBROSIS AND EMPHYSEMA: PATHWAY TO CHARACTERIZING CPFE. CHEST Journal. 164(4). A4011–A4012. 1 indexed citations
13.
Regan, Elizabeth A., Barry J. Make, MeiLan K. Han, et al.. (2022). Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With Smoking Exposure. CHEST Journal. 163(2). 292–302. 3 indexed citations
14.
Buhr, Russell G., Igor Barjaktarević, P. Miguel Quibrera, et al.. (2022). Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. American Journal of Respiratory and Critical Care Medicine. 206(5). 554–562. 22 indexed citations
15.
Labaki, Wassim W., Lucas Kimmig, Gökhan M. Mutlu, MeiLan K. Han, & Surya P. Bhatt. (2019). Update in Chronic Obstructive Pulmonary Disease 2018. American Journal of Respiratory and Critical Care Medicine. 199(12). 1462–1470. 3 indexed citations
16.
Fawzy, Ashraf, Nirupama Putcha, Laura M. Paulin, et al.. (2018). Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. Respiratory Research. 19(1). 20–20. 28 indexed citations
17.
Patel, Minal, Valerie G. Press, Lynn B. Gerald, et al.. (2018). Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease: An Official American Thoracic Society Policy Statement. American Journal of Respiratory and Critical Care Medicine. 198(11). 1367–1374. 33 indexed citations
18.
Washko, George R., Alejandro A. Díaz, R. Graham Barr, et al.. (2014). Computed tomographic measures of airway morphology in smokers and never-smoking normals. Journal of Applied Physiology. 116(6). 668–673. 46 indexed citations
19.
Sand, Jannie Marie Bülow, Federica Genovese, Fernando J. Martínez, et al.. (2013). Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients. European Respiratory Journal. 42(Suppl 57). P838–P838. 1 indexed citations
20.
Han, MeiLan K., Robert A. Wise, Jeanette A. Mumford, et al.. (2009). Prevalence and clinical correlates of bronchoreversibility in severe emphysema. European Respiratory Journal. 35(5). 1048–1056. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerard J. Criner Breakdown of academic impact, for papers by Frank C. Sciurba Breakdown of academic impact, for papers by Harvey O. Coxson Breakdown of academic impact, for papers by Barry J. Make Breakdown of academic impact, for papers by George R. Washko Breakdown of academic impact, for papers by Ruth Tal‐Singer Breakdown of academic impact, for papers by Mark T. Dransfield Breakdown of academic impact, for papers by Roberto Rodríguez-Roisin Breakdown of academic impact, for papers by Nicola A. Hanania Breakdown of academic impact, for papers by David A. Lomas
Rankless by CCL
2026